Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for BRAF-mutant melanoma. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist video case presentations
• Interactive audience polling and extensive Q&A

Topics to Be Discussed

• Identification of patients with BRAF-mutant melanoma appropriate for adjuvant therapy and selection among systemic treatment options
• First- and later-line therapeutic strategies for patients with BRAF-mutant melanoma
• Combination treatment with immunotherapy and targeted therapy for BRAF-mutant metastatic melanoma
• Adverse events associated with targeted therapies, immune checkpoint inhibitors and combination approaches for melanoma

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of BRAF-mutant melanoma.

Learning Objectives

• Identify patients after surgical removal of primary BRAF-mutant melanoma for whom adjuvant therapy should be considered, and counsel them about the risks and potential benefits of various systemic approaches.
• Consider patient age, performance status and other disease-related factors in the selection of first- and later-line therapy for BRAF-mutant metastatic melanoma.
• Use available clinical trial evidence to safely and effectively incorporate targeted, immunotherapeutic or combination therapy into the management of metastatic melanoma with a BRAF tumor mutation.
• Identify adverse events associated with targeted therapies, immune checkpoint inhibitors and combination approaches for melanoma, and offer supportive strategies to minimize and manage side effects.
• Recall available and emerging data with investigational strategies for BRAF-mutant melanoma, and where applicable, refer eligible patients for trial participation.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Long — Consultant Advisor: Aduro Biotech, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Evaxion Biotech A/S, Hexal AG, Highlight Therapeutics SL, Merck Sharp & Dohme Corp, Novartis, OncoSec Medical, Pierre Fabre, QBiotics, Regeneron Pharmaceuticals Inc, SkylineDx, Specialised Therapeutics. Dr Luke — Advisory Committee: 7 Hills Pharma LLC, AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Arch Oncology, F-star Therapeutics, Inzen Therapeutics, Kanaph Therapeutics, Onc.AI, Pyxis Oncology, RefleXion, Tempest Therapeutics, Xilio Therapeutics; Consulting Agreements: AbbVie Inc, Alnylam Pharmaceuticals Inc, Avillion LLP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Checkmate Pharmaceuticals, Codiak BioSciences, CrownBio, Day One Biopharmaceuticals, Eisai Inc, EMD Serono Inc, Flame Biosciences, Genentech, a member of the Roche Group, Gilead Sciences Inc, HotSpot Therapeutics, Ikena Oncology, Immunocore, Incyte Corporation, Janssen Biotech Inc, Kadmon, KSQ Therapeutics, MacroGenics Inc, Merck, Mersana Therapeutics, Nektar, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Ribon Therapeutics, Rubius Therapeutics, Silicon Therapeutics, Synlogic, Synthekine, TRex Bio, Werewolf Therapeutics, Xencor; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Day One Biopharmaceuticals, EMD Serono Inc, F-star Therapeutics, Genmab, Ikena Oncology, Immatics, Incyte Corporation, Kadmon, KAHR, MacroGenics Inc, Merck, Moderna, Nektar, NextCure, Numab, Pfizer Inc, Replimmune, Rubius Therapeutics, Scholar Rock, Synlogic, Takeda Pharmaceuticals USA Inc, Tizona Therapeutics Inc, Trishula Therapeutics Inc, Xencor; Data and Safety Monitoring Board/Committee: AbbVie Inc, Immutep; Ownership Interest: Actym Therapeutics, Alphamab Oncology, Arch Oncology, Kanaph Therapeutics, Onc.AI, Pyxis Oncology, Tempest Therapeutics. Dr Sznol — Consulting Agreements: AbbVie Inc, Adagene, Adaptimmune, Agenus Inc, Alligator Bioscience, Apexigen, Asher Bio, AstraZeneca Pharmaceuticals LP, Biond Biologics, BioNTech AG, Boehringer Ingelheim Pharmaceuticals Inc, Boston Pharmaceuticals, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co Ltd, Dragonfly Therapeutics, EvolveImmune, Genentech, a member of the Roche Group, Genocea, GI Innovation, Gilead Sciences Inc, GlaxoSmithKline, Idera Pharmaceuticals Inc, Immunocore, Incyte Corporation, Innate Pharma, iTeos Therapeutics, Jazz Pharmaceuticals Inc, Kadmon, Kanaph Therapeutics, Lilly, Molecular Partners, Nektar, NextCure, Numab, OncoSec Medical, Ontario Institute for Cancer Research, Pfizer Inc, Pieris Pharmaceuticals Inc, Pierre Fabre, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, RootPath, Rubius Therapeutics, Sapience Therapeutics Inc, Seagen Inc, Servier Pharmaceuticals LLC, Simcha Therapeutics, STCube, Targovax, Tessa Therapeutics, Trillium Therapeutics Inc, Verastem Inc, Zelluna Immunotherapy AS; Data and Safety Monitoring Board/Committee: BioNTech AG; Stock: GlaxoSmithKline, Johnson & Johnson Pharmaceuticals; Stock Options: Actym Therapeutics, Adaptive Biotechnologies Corporation, Amphivena Therapeutics Inc, Asher Bio, EvolveImmune, Intensity Therapeutics, Nanobot, NextCure, OncoHost, Torque Therapeutics (Repertoire Immune Medicines). Dr Weber — Advisory Board: Bristol-Myers Squibb Company; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Biond Biologics, Celldex Therapeutics, EMD Serono Inc, Evaxion Biotech A/S, Genentech, a member of the Roche Group, GlaxoSmithKline, ImCheck Therapeutics, Incyte Corporation, Merck, Nektar, Novartis, Pfizer Inc, SELLAS Life Sciences; (Contracted Research to Institution Only); Data and Safety Monitoring Board/Committee: Ultimovacs; Patents: Filed by Biodesix, Moffitt Cancer Center; Scientific Advisory Board: Biond Biologics, Evaxion Biotech A/S, ImCheck Therapeutics, Instil Bio Inc, NexImmune, OncoC4, SELLAS Life Sciences.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from Novartis and Pfizer Inc.